The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells

Leukemia

Volumn 29, Issue 1, 2015, Pages 96-106

  Lopez Guerra M ^a   Xargay Torrent, S ^a   Rosich, L ^a   Montraveta, A ^a   Roldan J ^a   Matas Cespedes A ^a   Villamor, N ^b   Aymerich, M ^b   Lopez Otin C ^c   Perez Galan P ^a   Roue G ^a   Campo, E ^b   Colomer, D ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GELATINASE B; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 32; LENALIDOMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NOTCH1 RECEPTOR; PF 3084014; PREDNISONE; RAC2 PROTEIN; VINCRISTINE; 2-(5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-3-YLAMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE; ENZYME INHIBITOR; NOTCH1 PROTEIN, HUMAN; SECRETASE; TETRALIN DERIVATIVE; VALINE; VIDARABINE;

ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL INVASION; CELL MIGRATION; CHEMOTAXIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; GENE; GENE MUTATION; GENETIC TRANSCRIPTION; HRK GENE; HUMAN; HUMAN CELL; IL32 GENE; LEUKEMIA CELL; MALE; MMP9 GENE; NOTCH1 GENE; RAC2 GENE; SIGNAL TRANSDUCTION; STROMA; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; GENETICS; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL CULTURE;

AGED; AMYLOID PRECURSOR PROTEIN SECRETASES; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, NOTCH1; TETRAHYDRONAPHTHALENES; TUMOR CELLS, CULTURED; VALINE; VIDARABINE;

EID: 84920695988     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.143     Document Type: Article

References (39)

1. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211-219.
2. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
3. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
4. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44: 47-52.
5. Ramsay AJ, Quesada V, Foronda M, Conde L, Martinez-Trillos A, Villamor N et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet 2013; 45: 526-530.
6. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-2506.
7. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389-1401.
8. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521-529.
9. Weissmann S, Roller A, Jeromin S, Hernandez M, Abaigar M, Hernandez-Rivas JM et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lym-phocytic leukemia (CLL): a study on 852 patients. Leukemia 2013; 27: 2393-2396.
10. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006; 7: 678-689.
11. Rosati E, Sabatini R, Rampino G, Tabilio A, Di IM, Fettucciari K et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113: 856-865.
12. Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 2013; 28: 1060-1070.
13. Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013; 27: 1100-1106.
14. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
15. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010; 9: 1618-1628.
16. Samon JB, Castillo-Martin M, Hadler M, mbesi-Impiobato A, Paietta E, Racevskis J et al. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012; 11: 1565-1575.
17. Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lym-phocytic leukemia. Leukemia 2007; 21: 1-3.
18. Rosich L, Saborit-Villarroya I, Lopez-Guerra M, Xargay-Torrent S, Montraveta A, Aymerich M et al. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica 2013; 98: 1739-1747.
19. Kim HS, Zhang X, Choi YS. Activation and proliferation of follicular dendritic celllike cells by activated T lymphocytes. J Immunol 1994; 153: 2951-2961.
20. Xargay-Torrent S, Lopez-Guerra M, Saborit-Villarroya I, Rosich L, Campo E, Roue G et al. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin Cancer Res 2011; 17: 3956-3968.
21. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006; 103: 18261-18266.
22. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004; 104: 1428-1434.
23. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18: 268-281.
24. Rosati E, Sabatini R, De FF, Del PB, Falzetti F, Di IM et al. Gamma-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. Int J Cancer 2013; 132: 1940-1953.
25. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
26. Nakamura M, Shimada K, Konishi N. The role of HRK gene in human cancer. Oncogene 2008; 27(Suppl 1): S105-S113.
27. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309.
28. Nwabo Kamdje AH, Bassi G, Pacelli L, Malpeli G, Amati E, Nichele I et al. Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. Blood Cancer J 2012; 2: e73.
29. Letilovic T, Vrhovac R, Verstovsek S, Jaksic B, Ferrajoli A. Role of angiogenesis in chronic lymphocytic leukemia. Cancer 2006; 107: 925-934.
30. Funahashi Y, Shawber CJ, Sharma A, Kanamaru E, Choi YK, Kitajewski J. Notch modulates VEGF action in endothelial cells by inducing matrix metalloprotease activity. Vasc Cell 2011; 3: 2.
31. Wang J, Fu L, Gu F, Ma Y. Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep 2011; 26: 1295-1303.
32. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006; 66: 2778-2784.
33. Garg P, Jeppsson S, Dalmasso G, Ghaleb AM, McConnell BB, Yang VW et al. Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-associated cancer in mice. Gastroenterology 2011; 141: 1381-1392.
34. Redondo-Munoz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hernandez del CM, Roderfeld M et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010; 17: 160-172.
35. Kamiguti AS, Lee ES, Till KJ, Harris RJ, Glenn MA, Lin K et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol 2004; 125: 128-140.
36. Buggins AG, Levi A, Gohil S, Fishlock K, Patten PE, Calle Y et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011; 154: 216-222.
37. Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LA. Interleukin 32 (IL-32) contains a typical alpha-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem 2012; 287: 5733-5743.
38. Sai J, Raman D, Liu Y, Wikswo J, Richmond A. Parallel phosphatidylinositol 3-kinase (PI3K)-dependent and Src-dependent pathways lead to CXCL8-mediated Rac2 activation and chemotaxis. J Biol Chem 2008; 283: 26538-26547.
39. Niggli V, Schlicht D, Affentranger S. Specific roles of Rac1 and Rac2 in motile functions of HT1080 fibrosarcoma cells. Biochem Biophys Res Commun 2009; 386: 688-692.